Harvard Bioscience
HBIO
98 hedge funds and large institutions have $187M invested in Harvard Bioscience in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 27 increasing their positions, 40 reducing their positions, and 12 closing their positions.
700% more call options, than puts
Call options by funds: $32K | Put options by funds: $4K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.03% less ownership
Funds ownership: 7.35% → 7.32% (-0.03%)
5% less funds holding
Funds holding: 103 → 98 (-5)
11% less capital invested
Capital invested by funds: $211M → $187M (-$24M)
33% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 40
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
Harvey Partners
Tarrytown,
New York
|
+$5.68M |
| 2 |
PAIM
Punch & Associates Investment Management
Edina,
Minnesota
|
+$1.77M |
| 3 |
2C
272 Capital
Dallas,
Texas
|
+$1.73M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.29M |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$572K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Acuitas Investments
Seattle,
Washington
|
-$3.05M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$1.19M |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$1.03M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$785K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$769K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RJA
101
Raymond James & Associates
St Petersburg,
Florida
| – | -$240K | -3,402 | Closed |
|
102
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$163K | -2,306 | Closed |
|
|
B
103
Bailard
Foster City,
California
| – | -$104K | -1,470 | Closed |
|
104
Squarepoint
New York
| – | -$94K | -1,340 | Closed |
|
|
WG
105
Winton Group
London,
United Kingdom
| – | -$86K | -1,222 | Closed |
|
|
DWA
106
Dorsey Wright & Associates
Pasadena,
California
| – | -$55K | -774 | Closed |
|
107
Simplex Trading
Chicago,
Illinois
| – | -$9.82K | -166 | Closed |
|
108
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$6K | -85 | Closed |
|
|
TCWM
109
Total Clarity Wealth Management
St. Charles,
Illinois
| – | -$6K | -81 | Closed |
|
110
Group One Trading
Chicago,
Illinois
| – | -$1.77K | -30 | Closed |
|
HBIO Hedge Fund Activity: Q1 2022 in Review
98 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q1 2022, worth a combined $187M — down 11% from $211M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of HBIO and 8 opened new positions — a net loss of 4 holders — while 40 trimmed existing stakes and 27 added.
The largest buyer was Harvey Partners, adding an estimated $5.68M. The largest seller was Acuitas Investments, exiting entirely with an estimated $3.05M sold.
- 98 institutional investors held Harvard Bioscience (HBIO) as of Q1 2022, down from 103 in Q4 2021.
- Funds reported $187M of Harvard Bioscience stock for Q1 2022, down 11% quarter-over-quarter.
- 8 funds opened new Harvard Bioscience positions in Q1 2022 and 12 closed out, a net change of -4 holders.
- The largest Harvard Bioscience buyer in Q1 2022 was Harvey Partners, an estimated $5.68M added.
- The largest Harvard Bioscience seller in Q1 2022 was Acuitas Investments, an estimated $3.05M sold.
Based on aggregated 13F filings for Q1 2022.